[1]
|
Jemal, A., et al. (2010) Cancer statistics. CA: A Cancer Journal for Clinicians, 60, 277-300.
doi:10.3322/caac.20073
|
[2]
|
Pfister, D.G., et al. (2004) American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. Journal of Clinical Oncology, 22, 330-53. doi:10.1200/JCO.2004.09.053
|
[3]
|
Lawrence, T., Ten Haken, R. and Giaccia, A. (2008) Principles of radiation oncology. In: De Vita, V., Lawrence, T. and Rosenberg, S., Eds., Cancer: Principles and practice of oncology, 8th Edition, Lippincott Williams and Wilkins, Philadelphia.
|
[4]
|
Johnson, D.H., et al. (1990) Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Annals of Internal Medicine, 113, 33-38.
|
[5]
|
Joss, R.A., et al. (1984) New agents in non-small cell lung cancer. Cancer Treatment Reviews, 11, 205-236.
doi:10.1016/0305-7372(84)90009-4
|
[6]
|
Furuse, K., et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. Journal of Clinical Oncology, 17, 2692-2699.
|
[7]
|
Fournel, P., et al. (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie thoracique-groupe Francais de pneumo-cancerologie NPC 95-01 study. Journal of Clinical Oncology, 23, 5910-5917.
doi:10.1200/JCO.2005.03.070
|
[8]
|
Curran, W.J. Jr., et al. (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. Journal of the National Cancer Institute, 103, 1452-1460.
doi:10.1093/jnci/djr325
|
[9]
|
Bonomi, P., et al. (2003) Randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Report of locally advanced multimodality protocol (LAMP)-ACR 427. Lung Cancer, 41, S77.
|
[10]
|
Zemanova, M., Petruzelka, L., et al. (2002) Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study (abst). Proceedings of the American Society of Clinical Oncology, 21, 290a.
|
[11]
|
Loehrer, P.J. and Einhorn, L.H. (1984) Drugs five years later cisplatin. Annals of Internal Medicine, 100, 704-713.
|
[12]
|
Rozencweig, M., et al. (1977) Cis-diamminedichloroplatinum (II). A new anticancer drug. Annals of Internal Medicine, 86, 803-812.
|
[13]
|
Prestayko, A.W., et al. (1979) Cisplatin (cis-diammine- dichloroplatinum II). Cancer Treatment Reviews, 6, 17-39.
doi:10.1016/S0305-7372(79)80057-2
|
[14]
|
Schaake-Koning, C., et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. The New England Journal of Medicine, 326, 524-530.doi:10.1056/NEJM199202203260805
|
[15]
|
Gralla, R.J., Cvitkovic, E. and Golbey, R.B. (1979) cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung. Cancer Treatment Report, 63, 1585-1588.
|
[16]
|
McKeage, M.J., et al. (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. Journal of Clinical Oncology, 15, 2691-2700.
|
[17]
|
Kurata, T., et al. (2000) Pharmacokinetic and pharmaco- dynamic analysis of bis-acetato-ammine-dichlorocyclo-hexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: A phase I study. Japanese Journal of Clinical Oncology, 30, 377-384.
doi:10.1093/jjco/hyd102
|
[18]
|
(2004) Satraplatin, GPC biotech investigator’s brochure.
|
[19]
|
Twentyman, P.R., et al. (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Research, 52, 5674-5680.
|
[20]
|
Amorino, G.P., et al. (1999) Radiopotentiation by the oral platinum agent, JM216: Role of repair inhibition. International Journal of Radiation Oncology & Biology & Physics, 44, 399-405.
doi:10.1016/S0360-3016(99)00033-4
|
[21]
|
Amorino, G.P., et al. (2000) Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemotherapy and Pharmacology, 46, 423-426. doi:10.1007/s002800000169
|
[22]
|
Choy, H., Park, C. and Yao, M. (2008) Current status and future prospects for Satraplatin, an oral platinum analogue. Clinical Cancer Research, 14, 1633-1638.
doi:10.1158/1078-0432.CCR-07-2176
|
[23]
|
George, C.M., et al. (2001) A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Investigational New Drugs, 19, 303-310. doi:10.1023/A:1010653508700
|
[24]
|
Cmelak, A.J., et al. (1999) Phase I study of JM-216 with con-current radiation in non-small cell lung cancer and squamous cell head and neck cancer (abstr). Proceedings of the American Society of Clinical Oncology, 18, 393a.
|
[25]
|
Brookmeyer, R. and Crowley, J. (1982) A confidence interval for the median survival time. Biometrics, 38, 29-41. doi:10.2307/2530286
|
[26]
|
Bartelink, H. (1988) Combined modality treatment for primary tumor. National Cancer Institute Monograph, 1988, 247-251.
|
[27]
|
Steel, G.G. (1988) The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiotherapy & Oncology, 11, 31-53.
doi:10.1016/0167-8140(88)90044-8
|
[28]
|
Dillman, R.O., et al. (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. The New England Journal of Medicine, 323, 940-845.
doi:10.1056/NEJM199010043231403
|
[29]
|
Sause, W., et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest, 117, 358-364. doi:10.1378/chest.117.2.358
|
[30]
|
Klastersky, J., et al. (1989) Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung cancer working party, Belgium. Journal of Clinical Oncology, 7, 1087-1092.
|
[31]
|
Wozniak, A.J., et al. (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A southwest on- cology group study. Journal of Clinical Oncology, 16, 2459-2465.
|
[32]
|
Dillman, R.O., et al. (1996) Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. Journal of the National Cancer Institute, 88, 1210-1215.
doi:10.1093/jnci/88.17.1210
|
[33]
|
Sause, W.T., et al. (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. Journal of the National Cancer Institute, 87, 198-205. doi:10.1093/jnci/87.3.198
|
[34]
|
Sorensen, J.B., Clerici, M. and Hansen, H.H. (1988) Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemotherapy and Pharma- cology, 21, 89-102. doi:10.1007/BF00257354
|
[35]
|
Bartelink, H., et al. (1988) Combined treatment with radiation and anticancer drugs: Experimental and clinical results. In: Bartelink, H., Ed., Radiobiology in Radiotherapy, Springer-Verlag, London, 177-179.
|
[36]
|
Begg, A., Stewart, F. and Dewit, L. (1987) Interactions between cisplatin and radiation in experimental rodent tumors and normal tissues. Antitumor drug-radiation interactions. CRC Press, Boca Raton, 154-170.
|
[37]
|
Douple, E.B. and Richmond, R.C. (1979) Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). International Journal of Radiation Oncology & Biology & Physics, 5, 1369-1372.
doi:10.1016/0360-3016(79)90672-2
|
[38]
|
Von der Maase, H., Overgaard, J. and Vaeth, M. (1986) Effect of cancer chemotherapeutic drugs on radiation- induced lung damage in mice. Radiotherapy & Oncology, 5, 245-257. doi:10.1016/S0167-8140(86)80054-8
|
[39]
|
Bartelink, H., et al. (1986) Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiotherapy & Oncology, 6, 61-74.
doi:10.1016/S0167-8140(86)80110-4
|
[40]
|
Lelieveld, P., et al. (1985) The effect of treatment in frac- tionated schedules with the combination of X-irradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin. International Journal of Radiation Oncology & Biology & Physics, 11, 111-121.
doi:10.1016/0360-3016(85)90369-4
|
[41]
|
Tanabe, M., Godat, D. and Kallman, R.F. (1987) Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse. International Journal of Radiation Oncology & Biology & Physics, 13, 1523-1532. doi:10.1016/0360-3016(87)90320-8
|
[42]
|
Begg, A.C., Bohlken, S. and Bartelink, H. (1989) The effect of cisplatin on the repair of radiation damage in RIF1 mouse tumours in vivo. Radiotherapy & Oncology, 15, 79-91. doi:10.1016/0167-8140(89)90121-7
|
[43]
|
Squibb, B.-M. (1998) Phase I study of oral bis (acetato) amine dichloro cyclohexylamine platinum (IV) (Satraplatin, JM-216) given daily x 5 (CA142-003/CA142-009). Bristol-Myers Squibb Interim Safety Report Accession No. 9100663081998.
|
[44]
|
Squibb, B.-M. (1999) Phase I/II study with JM-216 and simultaneous radiation in locally advanced non-small cell lung and head and neck cancer (CA142-020), 1999.
|